CClinicalTrials.gg
CompletedNCT07058051Updated Nov 19, 2025

Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in China

An observational study in Non-Segmental Vitiligo, sponsored by AbbVie. Completed at 4 sites in China. Open to participants aged 12 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-11-19.

Sponsored by AbbVie · Observational

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
100
Ages
12 Years to 99 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the patterns of treatment, healthcare resources utilized and the burdens associated with non-segmental vitiligo (NSV) amongst participants in China

This study is a cross-sectional, multicenter, observational study of vitiligo patients in China. The cross-sectional design is sufficient to characterize the overall current burden of NSV.

Read the detailed description

Cross-Sectional

02

Conditions studied

  • Non-Segmental Vitiligo
03

In context

Lead sponsor

AbbVie is the lead sponsor of 953 studies on the registry; 136 are open to participants now.

Of its 350 completed or terminated interventional studies of FDA-regulated products, 210 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Chinese patients with non-segmental vitiligo and 5≤T-VASI\<50 will be included. The NSV patients will be consecutively enrolled via convenience sampling in this study.

Inclusion criteria

  • Male and female patients, age ≥ 12.
  • Chinese patients meet the diagnosis of Non-Segmental Vitiligo (NSV) and 5≤ Total Vitiligo Area Scoring Index (T-VASI\<50) with or without facial involvement.
  • Medical history available within the last 6 months.
  • Ability to understand the questionnaires, with parental support as required for adolescents (between ≥ 12 and \< 18 years of age at inclusion visit).
  • Willing to provide a patient authorization form to use and disclose personal health information (or informed consent, where applicable) to participate in the study; for adolescent subjects, authorization and/or consent will be provided by a parent or legal guardian, where applicable.

Exclusion criteria

Exclusion Criteria:

  • Unable or unwilling to comply with study requirements and electronic Patient-Reported Outcome (ePRO) collection.
  • Segmental or localized vitiligo.
  • Greater than 33% leukotrichia in areas of vitiligo on the face or on the body.
  • History of active skin disease other than vitiligo that could interfere with the assessment of vitiligo.
  • Patients who are participating in interventional clinical trial(s) at time of study visit.
  • Patients who are currently receiving treatment with any investigational drug/device/intervention or have received any investigational product within 1 month or 5 half-lives of the investigational agent (whichever is longer) prior to enrollment.
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
100 participants (actual)
06

What researchers measure

Primary outcomes

  1. Total Vitiligo Area Scoring Index (T-VASI)

    The T-VASI is calculated using a formula that includes contributions from all body regions, with a possible range from 0 to 100, with higher scores indicating more severe disease.

    Time frame: At Inclusion Visit (Day 1)

  2. Vitiligo Quality of Life Scale (VitiQoL)

    The VitiQoL is an 16-item instrument assessing impact of vitiligo on quality of life. 15 items are scored on a 7-point Likert scale, ranging from "not at all" to "all the time". An additional item (not contributing to total score) assesses current severity of condition on a 7-point scale ranging from "no skin involvement" to "most severe case"

    Time frame: At Inclusion Visit (Day 1)

07

Study locations

4 sites
  • Dermatology Hospital of Southern Medical University /ID# 276921
    Guangzhou, Guangdong 510091, China
  • Wuhan Integrated TCM & Western Medicine Hospital(Wuhan No.1 Hospital) /ID# 276919
    Wuhan, Hubei 430022, China
  • Suzhou Municipal Hospital /ID# 276948
    Suzhou, Jiangsu 215002, China
  • Shandong Dermatological Hospital /ID# 276918
    Jinan, Shandong 250022, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07058051
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jul 10, 2025
Start date
Jul 17, 2025
Primary completion
Nov 13, 2025
Completion
Nov 13, 2025
Last update
Nov 19, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

AbbVie

Start the discussion